What it sells
Tradewind translates scientific insight into innovative ways of…
Business model breakdown
Buyer: who owns the budget?
UnverifiedNot applicable to a customer sale; likely pharma partners or investors.
Workflow: what inputs become what output?
Drug discovery: first program is an inhibitory antibody against a secreted oncogenic protein for late-stage ovarian cancer, paired with companion diagnostics/biomarkers to select patients.
Economics: what it saves and how it charges
UnverifiedPre-revenue therapeutics developer; value comes from drug development and eventual licensing or commercialization.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2018 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.